There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GeoVax Labs (GOVX – Research Report), Tango Therapeutics (TNGX – Research Report) and Alcon (ALC – Research Report) with bullish sentiments.
Stay Ahead of the Market:
GeoVax Labs (GOVX)
In a report released today, Robert LeBoyer from Noble Financial reiterated a Buy rating on GeoVax Labs, with a price target of $10.00. The company’s shares closed last Tuesday at $0.89.
According to TipRanks.com, LeBoyer is ranked 0 out of 5 stars with an average return of -12.8% and a 26.3% success rate. LeBoyer covers the Healthcare sector, focusing on stocks such as Cadrenal Therapeutics, Inc., MAIA Biotechnology, Inc., and Eledon Pharmaceuticals.
Currently, the analyst consensus on GeoVax Labs is a Strong Buy with an average price target of $16.25, which is a 1983.3% upside from current levels. In a report issued on April 10, Roth MKM also maintained a Buy rating on the stock with a $20.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Tango Therapeutics (TNGX)
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Tango Therapeutics yesterday and set a price target of $13.00. The company’s shares closed last Tuesday at $1.39.
According to TipRanks.com, Burns is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -24.6% and a 23.0% success rate. Burns covers the Healthcare sector, focusing on stocks such as Black Diamond Therapeutics, Bicara Therapeutics Inc., and CARGO Therapeutics, Inc.
Currently, the analyst consensus on Tango Therapeutics is a Moderate Buy with an average price target of $11.50.
Alcon (ALC)
In a report released yesterday, Ryan Zimmerman from BTIG maintained a Buy rating on Alcon, with a price target of $102.00. The company’s shares closed last Tuesday at $91.36.
According to TipRanks.com, Zimmerman has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -4.1% and a 39.9% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as GE Healthcare Technologies Inc, Tactile Systems Technology, and Treace Medical Concepts.
Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $111.36, which is a 21.2% upside from current levels. In a report issued on March 31, KeyBanc also maintained a Buy rating on the stock with a $112.00 price target.
Read More on GOVX: